Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Teva's at-risk strategy produces another muddled outcome as the generic firm now owes Novartis royalties on U.S. sales of its generic version of the herpes drug.

You may also be interested in...



At-Risk Launches: Three Cases May Determine How Damages Are Calculated

How risky are at-risk launches of generic products?

At-Risk Launches: Three Cases May Determine How Damages Are Calculated

How risky are at-risk launches of generic products?

Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix

A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope

US WorldMeds’ Eflornithine Gets US FDA Panel Nod For Pediatric Neuroblastoma

US FDA Versus Its Own Precedents

US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

See All
UsernamePublicRestriction

Register

PS070231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By